newsfilter
← Latest News
GlobeNewswire·

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with